中国快讯 (ChinaCrunch) 为中国读者提供及时的加密新闻、市场洞察和监管动态。
Gilead acquires Ouro Medicines in multibillion deal securing China linked antibody therapy rights
Gilead Sciences has agreed to acquire US based biotech firm Ouro Medicines in a deal valued at up to 2.18 billion dollars, gaining access to a promising antibody based treatment originally licensed from China’s Keymed Biosciences. The transaction highlights the growing importance of